MERCK & CO INC

Merck’s stock climbs as investors favor defensive healthcare amid easing geopolitics and oil volatility, showing robust earnings and a resilient pipeline.

Merck’s 29 June 2026 share rise shows a resilient healthcare stock: strong valuation, growth‑oriented R&D, value‑based care strategy, and cost‑efficient operations that boost investor confidence.

Merck’s MRK gains amid market rotation, driven by its cardiometabolic, oncology, vaccine, and cell‑therapy breakthroughs—showing resilience and value for investors.

Merck’s modest stock rise on a weak day is fueled by its new Alger Russell Innovation Index spot, attractive macro‑valuation, and oncology gains – a clear value play for healthcare investors.

Merck expands its animal‑health reach with a poultry automation deal, a gene‑therapy partnership for companion animals, and stronger precision‑oncology diagnostics—boosting growth while offsetting patent cliffs.

Merck & Co. navigates a Frankfurt Stock Exchange outage while advancing mRNA cancer vaccines and space‑based drug trials, showcasing resilience and innovation.

Discover how Merck & Co. and Kelun‑Biotech are leveraging AI-driven trials and strategic pricing to capture U.S. and Chinese oncology markets amid bullish equity trends.

Merck’s latest 8‑K shows a promising lung‑cancer trial and a new debt deal that fuels R&D and boosts investor confidence—highlighting the firm’s strategy to win value‑based pricing and expand access amid a competitive oncology landscape.

Merck’s May 15 shareholders meeting and Q3 earnings reveal the company’s oncology focus, patent‑cliff strategy and M&A plans for growth.

Merck’s new TROP‑2 antibody‑drug conjugate shows survival gains in endometrial and cervical cancers, while a Terns Pharma acquisition expands its CML pipeline and boosts oncology assets.